The Thermo Fisher Scientific Accula system is a rapid diagnostic point of care platform that provides simple, accurate sample-to-answer rapid PCR.
The Accula System consists of the Accula Dock and Accula Test Kit. The dock is a small, reusable device about the size of your palm that holds a cassette. It plugs into a standard electrical outlet and provides power to the cassette, which contains the components and reagents for viral lysis, reverse transcription, and PCR amplification. The Accula rapid PCR Tests provide reliable, qualitative PCR results in ~30 minutes.
Accula rapid PCR testing products
The Accula System workflow is elegantly simple: swab, elute, and follow the prompts on the dock to load the sample and run the test. Hands-on time is ~1 minute, after which you can walk away. The dock notifies you to read the results when the test is complete.
How it works
The Accula System is a rapid diagnostic platform that combines the accuracy of RT-PCR with the simplicity, convenience, and procedural familiarity of traditional rapid immunoassays. The Accula SARS-CoV-2 Test has received an Emergency Use Authorization (EUA) from the FDA for the detection of SARS-CoV-2 in Clinical Laboratory Improvement Amendments (CLIA)–waived environments. Designed for use with the palm-sized Accula Dock, the Accula SARS-CoV-2 Test provides reliable, qualitative results in approximately 30 minutes.
What customers are saying
There's a significant edge to rapid PCR technology. It makes testing programs a lot more convenient, while imparting greater confidence.
– Dr. Vin Gupta, Critical Care Pulmonologist and Professor at the University of Washington’s Institute for Health Metrics and Evaluation
A good thing about this equipment is you can set up a testing area in a small space. It’s amazing.
– Paula Smith, Head of School, University Child Development School
The most important factor was the accuracy of the test. Number two was convenience. Having both of those made it a no brainer to incorporate Accula tests as the primary means of testing.
– James Murphy, ProAm founder and CEO
People wanted a more sensitive, more specific test to confirm their diagnosis. We felt better being able to offer a molecular option.
– Seth Beltran, Director of Point of Care Services
Available through these distributors
For Emergency Use Authorization (EUA) Only. For prescription use only. For in vitro diagnostic use.